Clinical TrialJun 10, 2026, 07:39 AM
Artelo Biosciences' ART26.12 shows low-risk metabolite profile
AI Summary
Artelo Biosciences announced encouraging metabolite identification and profiling data for its lead FABP inhibitor candidate, ART26.12, from a recently completed Single Ascending Dose (SAD) clinical study. The data, presented at a conference, showed a low-risk metabolite profile with only three metabolites detected, representing approximately 7% of total drug-related exposure. These findings are expected to streamline future development, reduce program risk, and strengthen confidence in ART26.12's advancement for pain treatment.
Key Highlights
- Only three metabolites were detected from plasma of healthy volunteers administered a single 900 mg oral dose of ART26.12.
- Total metabolite exposure represented approximately 7% of overall drug-related exposure.
- The primary metabolite, accounting for approximately 5% of total drug-related exposure, was identified with comparable biological activity to ART26.12.
- All three human metabolites were previously detected in nonclinical toxicology studies and are of no safety concern.
- The low-risk metabolite profile is expected to simplify future development activities and reduce program risk.
- The data strengthens confidence in ART26.12, adding to positive dose-proportional pharmacokinetics, safety, and tolerability.
- Absence of human-specific metabolites and low overall metabolite burden is expected to reduce future development complexity, timelines, and cost.
Price Impact
More from ARTL